The data suggested that the patients with CR or near-CR receiving low-dose GCs maintenance therapy had milder COVID-19 symptoms, higher quality of life, and lower IL-6 levels as compared to those who did not receive GCs therapy. The gene discussed is IL6; the disease is COVID-19.